BIO

#896
Bio-Rad Laboratories, Inc. Class A Common Stock
386.5 4 USD
0.00%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
385.43
386.66
Jahresspanne
236.73
396.23
Tagesänderung
-0.34%
Monatliche Änderung
+13.08%
6 month change
+40.25%
Jahresänderung
+14.80%
Vorheriger Schlusskurs
387.8 5
Open
386.3 9
Tief
385.4 3
Hoch
386.6 6
Volumen
128
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
BIO-RAD LABORATORIES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
BIO-RAD LABORATORIES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
BIO-RAD LABORATORIES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
BIO-RAD LABORATORIES, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
BIO-RAD LABORATORIES, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
BIO-RAD LABORATORIES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
BIO-RAD LABORATORIES, INC. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
BIO-RAD LABORATORIES, INC. annual report, FY2025
10-K
Current report, Q4 FY2025
BIO-RAD LABORATORIES, INC. current report, Q4 FY2025
8-K
Quarterly report, Q3 FY2025
BIO-RAD LABORATORIES, INC. quarterly report, Q3 FY2025
10-Q

BIO-RAD LABORATORIES, INC. annual report, Q4 FY2001

Full document

Business Context and Reporting Period

Company: BIO-RAD LABORATORIES, INC.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2001

Bio-Rad operates in two primary segments: Life Science (reagents, instruments, and software for research) and Clinical Diagnostics (tests for disease detection). The Company serves universities, hospitals, pharmaceutical manufacturers, and government agencies globally. In 2001, Bio-Rad continued a strategic shift by selling the majority of its analytical instruments product lines to focus on its core Life Science and Clinical Diagnostics segments. The Company maintains distribution channels in 30 countries and employs approximately 4,300 full-time employees.

Key Financial Metrics

Note: Specific revenue, profit, cash flow, and debt totals for the fiscal year are incorporated by reference in Exhibit 13.1 (Annual Report to Stockholders) and are not explicitly stated in the provided text. The following metrics are available from the filing text:

  • Research & Development (R&D) Expense: $76.5 million for 2001 (excluding $15.5 million of purchased in-process R&D). This compares to $68.1 million in 2000 and $51.2 million in 1999.
  • Reserve for Doubtful Accounts Receivable: Ended the year at $11.509 million (up from $10.255 million in 2000).
  • Valuation Allowance for Deferred Tax Assets: Ended the year at $12.802 million (down from $17.020 million in 2000).
  • Market Capitalization (Non-Affiliates): Approximately $568.3 million as of March 8, 2002 (Class A: $547.6M; Class B: $20.7M).
  • Customer Concentration: No single customer accounted for more than 2% of total net sales in 2001.

Material Changes and Strategic Shifts

  • Divestitures: During 2000 and 2001, the Company sold the majority of its analytical instruments product lines to concentrate resources on Life Science and Clinical Diagnostics.
  • Acquisition Integration: The Company continues to integrate Pasteur Sanofi Diagnostics (PSD), acquired in October 1999 for $210 million, which expanded its presence in HIV and infectious disease diagnostics, particularly in Latin America, Africa, and France.
  • Increased R&D Investment: R&D spending increased by approximately 12.3% year-over-year (from $68.1M to $76.5M), reflecting a continued commitment to product development.
  • Shareholder Actions: On February 4, 2002, shareholders approved proposals to reduce the par value of Class A and Class B common stock and to amend the Certificate of Incorporation.

Outlook, Risks, and Management Commentary

Management Outlook: Management emphasizes that R&D is a major driver of growth. The Company expects to continue developing new products and applications for existing products, consulting with scientific professionals to drive innovation.

Risks and Contingencies:

  • Government Funding Dependence: A significant portion of the Life Science segment's customers rely on government grants. A reduction in funding could detrimentally affect results.
  • Regulatory Compliance: Products are subject to strict FDA regulations (pre-marketing approval, good manufacturing practices) and international safety/emissions standards. Non-compliance could halt sales.
  • Environmental Liability: The Company faces potential liabilities for spills or releases of hazardous substances at its properties.
  • Seasonality: European summer vacation customs typically negatively impact third-quarter sales volume and operating income.
  • Competition: Markets are competitive with no single dominant player, though competitors include major firms like Abbott Laboratories, Roche Diagnostics, and Applied Biosystems.

Investor Verification Checklist

  • Financial Statements: Verify total Net Sales, Net Income, and Operating Cash Flow in Exhibit 13.1 (Annual Report to Stockholders), as these figures are not present in the 10-K text provided.
  • Debt Obligations: Review the Credit Agreements (Exhibits 4.1, 4.2, 4.4) and Senior Subordinated Notes (Exhibit 4.5) to confirm total debt principal and interest rates.
  • Segment Performance: Consult Note 14 in Exhibit 13.1 for a breakdown of revenue and operating income by Life Science and Clinical Diagnostics segments.
  • Legal Proceedings: Review Note 13 in Exhibit 13.1 for details on pending litigation.
  • Divestiture Impact: Assess the financial impact of the analytical instruments divestitures on future revenue streams.